CYP2C9*3 gene variant contributes independently to glycaemic control in patients with type 2 diabetes treated with glibenclamide

Journal of Clinical Pharmacy and Therapeutics, EarlyView.

Source: Journal of Clinical Pharmacy and Therapeutics - May 26, 2018 Category: Drugs & Pharmacology Authors: O. D. Castel án‐Martínez PhD , C. Hoyo‐Vadillo PhD , T. B. Bazán‐Soto BSc , M. Cruz PhD , E. Tesoro‐Cruz PhD , A. Valladares‐Salgado PhD Source Type: research